ArticleAnnals of surgical oncology2026
Zip-Code Level Disadvantage as a Predictor of Metastatic Breast Cancer at Diagnosis and Delayed Treatment Initiation.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases.Annals of surgical oncology · 2026Article
- Evolution of Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundMetastatic breast cancer remains a significant public health issue, associated with worse outcomes and limited treatment options. While tumor biology influences disease progression, social and geographic disparities also contribute to late-stage diagnosis. The Distressed Communities Index (DCI), a zip-code level measure of economic hardship, captures structural disadvantage more comprehensively than traditional socioeconomic indicators. This study evaluates whether higher DCI scores are associated with metastatic stage and treatment delays, independent of clinical and demographic factors. PATIENTS AND
methodsWe conducted a retrospective cohort study of women aged ≥ 18 years diagnosed or treated for in situ (DCIS) and invasive breast cancer (2018-2022) at a comprehensive cancer center. Zip codes were linked to DCI scores. Multinomial logistic regression, adjusted for age, race, ethnicity, insurance status, tumor subtype, and clinical palpable mass, assessed the association between DCI and cancer stage. Analysis of covariance compared time with treatment across DCI groups.
resultsAmong 2024 women (38% Black, 39% Hispanic), 76.8% resided in high DCI areas. High DCI was associated with twice the likelihood of metastatic disease at diagnosis compared with localized stage (ref: low DCI, aOR 2.16, 95% CI 2.00-2.34, p < 0.001) after adjustment. High DCI patients also experienced longer time to treatment initiation, including adjuvant chemotherapy (119 versus 137 days, p = 0.024), radiation (103 versus 133 days, p < 0.001), and surgery (71.2 versus 87.4 days, p < 0.001), after adjustment for stage.
conclusionsLeveraging DCI may help identify high-risk zip codes and guide targeted screening to reduce disparities in outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.